Phase II Trial of Sacituzumab Tirumotecan and Tagitanlimab in Advanced Esophageal and Gastric Cancers
A phase II trial is underway to assess the efficacy and safety of sacituzumab tirumotecan combined with tagitanlimab in patients with recurrent or metastatic esophageal squamous cell carcinoma and gastric adenocarcinoma.
Phase II
esophageal squamous cell carcinoma
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase II trial of sacituzumab tirumotecan combined with tagitanlimab represents a significant opportunity to establish a new second-line treatment option in a market with limited effective therapies. Success could enhance the portfolio of Sun Yat-sen University and attract strategic partnerships in oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress and preliminary efficacy results from the safety lead-in phase.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.